Reijnders JG, Perquin MJ, Zhang N, et al. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology. 2010;139(2):491–8.
Sonneveld MJ. Chronic hepatitis B: peginterferon or nucleos(t)ide analogues? Liver Int. 2011;31 Suppl 1:78–84.
Hsu YS. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35(6):1522–7.
Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011–20.
Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–55.
Woo G. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology. 2010;139(4):1218–29.
Liaw YF. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci. 2010;55(10):2727–34.
Wiegand J. Management of chronic hepatitis B: status and challenges beyond treatment guidelines. Semin Liver Dis. 2010;30(4):361–77.
Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007;46(1):45–52.
Hadziyannis SJ. Milestones and perspectives in viral hepatitis B. Liver Int. 2011;31 Suppl 1:129–34.
Da Silva LC, Madruga CL, Carrilho FJ, et al. Spontaneous hepatitis B surface antigen clearance in a long-term follow-up study of patients with chronic type B hepatitis. Lack of correlation with hepatitis C and D virus superinfection. J Gastroenterol. 1996;31:696–701.
Kim JH, Lee YS, Lee HJ, et al. HBsAg seroclearance in chronic hepatitis B: implications for hepatocellular carcinoma. J Clin Gastroenterol. 2011;45(1):64–8.
• Lee JM, Ahn SH, Kim HS, et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology. 2011;53(5):1486–93. This study confirms that although the clinical outcomes after HBsAg seroclearance in CHB patients are favorable HCC, even the patients with HBsAg seroclearance may develop hepatocellular carcinoma, particularly those with evidence of cirrhosis at the time of HBsAg seroclearance.
•• Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886–93. The latest study confirming the reversal of fibrosis, even cirrhosis, in patients with chronic HBV infection, with a long-term antiviral therapy. This is most likely a class effect, associated with rare or no occurrence of antiviral resistance when using first-line therapeutic options such as entecavir or tenofovir.
Schiff ER. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2011;9(3):274–6.
Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65–73.
Loomba R, Yang Hi, Su J, et al. Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men. Clin Gastroenterol Hepatol. 2010;8(10):891–8.
Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–86.
•• Liu J, Yang HL, Lee MH, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology. 2010;139:474–482. The paper’s follow-up analysis on data stemming from the REVEAL study carried out in Taiwan suggests that low HBV DNA levels are an important factor affecting the natural seroclearance of HBsAg.